By MEGGLE Excipients
Subscribe to Supplier
Subscribe to Supplier
MEGGLE to address DPI formulation challenges at Respiratory Drugs Summit, Prague
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will be a prominent presence at the upcoming 2nd Respiratory Drugs Summit in the Czechia capital of Prague early next month.
MEGGLE is a principal sponsor of the event and will also contribute to a scientific agenda focusing on Formulation & Drug Delivery. MEGGLE Business Development Manager Inhalation, Dr. Constanze Mueller, will address the conference on ‘Challenges in DPI Formulation’.
Overcoming DPI formulation challenges
In her presentation, Dr. Mueller will review the main problems that can appear during formulation for Dry Powder Inhalation products with correct choices on excipients and blending being key elements in reaching ideal solutions.
She will show how MEGGLE’s InhaLac® range of DPI optimized lactose-based excipients greatly extends the options available to formulators.
Tailored DPI excipients
“We are very pleased to be attending this valuable conference” commented Dr. Mueller.
“We can show this expert audience what a substantial contribution MEGGLE can make to the DPI formulation field by developing very precisely tailored InhaLac® DPI lactose grades with particle sizes and flow characteristics optimized to a wide range of different therapeutic applications,” she added.
About MEGGLE
Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.
MEGGLE Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.
To learn more, visit: https://www.meggle-pharma.com/en/home.html
About Respiratory Drugs Summit 2023
The annual Respiratory Drugs Summit discusses the latest developments and breakthroughs in the field of respiratory medicine and explores new strategies for improving the health and quality of life of patients with respiratory diseases.
For 2023, the 2nd Respiratory Drugs Summit is focused on Formulation & Drug Delivery, focusing on topics such as nasal and pulmonary drug delivery, EU regulations, aerosol drug delivery, risks associated with nebulizer treatments, latest developments in smart and mesh inhalers and combination inhalers.
Following the inaugural 2022 summit in Munich, the 2023 summit will be a two-day event, opening October 5 at the Hotel Kings Court in the Czechia capital of Prague (Prahia).
The event is organized by Innovatrix, with further information at: https://innovatrix.eu/2nd-respiratory-drugs/
Resources
Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information.
Click on MEGGLE DPI technologies to view video.
MEGGLE InhaLac® sieved, milled and micronized lactose-based excipients support a wide range of Dry Powder Inhalation (DPI) applications.
Dr. Constanze Müller, MEGGLE Business Development Inhalation.
Related Articles
